Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To determine the adequacy of antocoagulation and impact of apixaban and rivaroxaban on individual obese patient's management

Trial Profile

To determine the adequacy of antocoagulation and impact of apixaban and rivaroxaban on individual obese patient's management

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2018

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
  • Indications Atrial fibrillation; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Dec 2018 New trial record
    • 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top